Sevirumab
Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CMV |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| ChemSpider |
|
| (verify) | |
References
- Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, et al. (November 2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
- Clinical trial number NCT00000836 for "A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.